Abnormal Brain Bioenergetics in First-Episode Psychosis

Prior research has shown that impaired brain energy metabolism is linked to schizophrenia and related psychotic conditions. However, the role of creatine kinase (CK) in these disorders remains unclear. While CK is essential for maintaining ATP levels during high energy demand, its activity has not been studied in first-episode psychosis (FEP) patients. Existing knowledge suggests that energy metabolism disruptions occur in later stages of the illness. This gap motivated researchers to investigate CK function during the initial phase of psychosis. No prior work had resolved whether CK dysfunction is an early or late feature of schizophrenia. Earlier studies focused on later stages or chronic patients, leaving FEP unexplored. This uncertainty drove the current study's design to examine CK in newly diagnosed patients. The goal was to determine whether bioenergetic issues manifest at the onset of illness.

This study aimed to assess brain bioenergetics in patients with first-episode psychosis (FEP) using phosphorus magnetization transfer spectroscopy. The researchers sought to measure CK activity in the frontal lobe, a region associated with cognitive and emotional processing. They wanted to determine if CK function is impaired in FEP compared to healthy controls. The motivation was to identify early metabolic changes that could inform treatment strategies. The study also aimed to examine other energy-related markers, such as phosphocreatine and ATP. Researchers were interested in whether these levels differ between FEP patients and controls. Another goal was to measure glycerol-3-phosphorylcholine, a potential marker of membrane breakdown. The overall aim was to explore the relationship between bioenergetic dysfunction and early psychosis.

The study employed phosphorus magnetization transfer spectroscopy to measure CK activity in vivo. Participants included 16 FEP patients and 34 healthy controls. Measurements were taken at rest in the frontal lobe, a region known for its metabolic activity. The primary outcome was the CK first-order forward rate constant (k). Researchers also assessed phosphocreatine (PCr) and ATP levels as secondary markers. Glycerol-3-phosphorylcholine was measured as a potential indicator of membrane turnover. The study used a cross-sectional design comparing FEP patients with controls. Data collection occurred in a single session for each participant.

CK activity, measured as the k constant, was significantly lower in FEP patients than in controls. This reduction suggests impaired energy metabolism in the frontal lobe of FEP patients. No significant differences were found in PCr or ATP levels between groups. Glycerol-3-phosphorylcholine levels were elevated in FEP patients compared to controls. This increase aligns with prior findings in medication-naïve patients. The elevated glycerol-3-phosphorylcholine may indicate increased membrane breakdown. These results suggest that bioenergetic dysfunction occurs early in psychosis. The findings support the hypothesis that metabolic changes precede clinical symptoms.

The study suggests that brain bioenergetic abnormalities are present early in schizophrenia spectrum disorders. Reduced CK activity in FEP patients indicates impaired energy metabolism. The results do not support a role for PCr or ATP in early-stage energy dysfunction. Elevated glycerol-3-phosphorylcholine levels are consistent with prior studies in FEP and schizophrenia. These findings may reflect increased synaptic pruning in early psychosis. The authors propose that future research should explore the link between CK dysfunction and symptom severity. They also suggest investigating treatments targeting the CK pathway. The study highlights the need for further research into early metabolic changes in psychosis.